News Release Archive http://pfizer.mediaroom.com/ Pfizer to Acquire FoldRx Pharmaceuticals http://pfizer.mediaroom.com/index.php?s=5149&item=13218 NEW YORK and CAMBRIDGE, Mass., Sept. 1 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) and FoldRx Pharmaceuticals, Inc. Wed, 01 Sep 2010 08:30:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=13218 MS LifeLines® Reaches Milestone of Servicing One Million In-Bound Calls http://pfizer.mediaroom.com/index.php?s=5149&item=13217 ROCKLAND, Mass. and NEW YORK, Sept. 1 /PRNewswire-FirstCall/ -- EMD Serono, Inc. and Pfizer Inc. Wed, 01 Sep 2010 08:00:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=13217 Bristol-Myers Squibb And Pfizer Inc. Evaluate Unmet Need In Patients With Atrial Fibrillation http://pfizer.mediaroom.com/index.php?s=5149&item=12846 Wed, 25 Aug 2010 13:45:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=12846 Topline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) http://pfizer.mediaroom.com/index.php?s=5149&item=12839 NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE :PFE) announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC). Mon, 23 Aug 2010 17:01:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=12839 World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children http://pfizer.mediaroom.com/index.php?s=5149&item=12836 NEW YORK, Aug. Mon, 23 Aug 2010 12:01:05 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=12836 Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A http://pfizer.mediaroom.com/index.php?s=5149&item=12797 NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Mon, 09 Aug 2010 10:00:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=12797 Pfizer Reports Second-Quarter 2010 Results http://pfizer.mediaroom.com/index.php?s=5149&item=11587 NEW YORK, Aug. 3 /PRNewswire-FirstCall/ --   Second-Quarter 2010 Revenues of $17.3 BillionSecond-Quarter 2010 Reported Diluted EPS(1) of $0.31, Adjusted Diluted EPS(2) of $0. Tue, 03 Aug 2010 07:00:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=11587 Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference http://pfizer.mediaroom.com/index.php?s=5149&item=11577 NEW YORK, July 29 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by David Simmons, President and General Manager, Established Products, at the BMO Capital Markets 10th Annual Focus On Healthcare Conference on Thursday, August 5, 2010 at 11:15 a.m. Eastern Daylight Time. Thu, 29 Jul 2010 10:00:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=11577 EISAI INC. AND PFIZER INC ANNOUNCE U.S. FDA APPROVAL FOR NEW HIGHER-DOSE ARICEPT® (DONEPEZIL HCL) 23 MG TABLET FOR THE TREATMENT OF MODERATE-TO-SEVERE ALZHEIMER’S DISEASE http://pfizer.mediaroom.com/index.php?s=5149&item=11557 Woodcliff Lake, NJ, and New York, July 23, 2010 ― Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer’s disease (AD). Fri, 23 Jul 2010 06:36:09 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=11557 Pfizer to Offer Free Public Access to Mental Health Assessment Tools to Improve Diagnosis and Patient Care http://pfizer.mediaroom.com/index.php?s=5149&item=11350 NEW YORK, July 22 /PRNewswire-FirstCall/ -- As part of its commitment to improving the quality of patient care, Pfizer (NYSE: PFE) today announced that it will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders. Thu, 22 Jul 2010 12:00:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=11350 Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need http://pfizer.mediaroom.com/index.php?s=5149&item=11206 NEW YORK, July 19 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Mon, 19 Jul 2010 17:01:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=11206 Pfizer and SMC Collaborate on Liver Cancer http://pfizer.mediaroom.com/index.php?s=5149&item=5790 NEW YORK, July 14 /PRNewswire-FirstCall/ -- Samsung Medical Center and the world's leading bio-pharmaceutical company Pfizer Inc. (NYSE: PFE) announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer. Wed, 14 Jul 2010 08:30:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=5790 New Research Presented at Alzheimer's Association International Conference on Alzheimer's Disease Indicates Alzheimer's Disease May Lead to Increased Comorbid Conditions and Economic Burden http://pfizer.mediaroom.com/index.php?s=5149&item=5782 HONOLULU, July 13 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer's Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (ICAD 2010) from two podium and four poster presentations. Tue, 13 Jul 2010 19:00:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=5782 Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimer's Association International Conference on Alzheimer's Disease http://pfizer.mediaroom.com/index.php?s=5149&item=5669 NEW YORK, July 8 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) will present new data on its investigational compounds targeting various aspects of Alzheimer's disease (AD), a complex degenerative brain disorder.  New findings on the role of comorbidities, the burden of care and costs associated with AD, also will be discussed. Thu, 08 Jul 2010 17:01:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=5669 Pfizer Strengthens Manufacturing Capabilities in Asia With Expansion of Singapore Nutrition Plant http://pfizer.mediaroom.com/index.php?s=5149&item=5667 SINGAPORE, July 7 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced a $100 million (U.S.) investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children. Wed, 07 Jul 2010 22:30:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=5667 Pfizer Invites Public to View and Listen to Webcast of August 3 Conference Call With Analysts http://pfizer.mediaroom.com/index.php?s=5149&item=5108 NEW YORK, June 29 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 3, 2010. Tue, 29 Jun 2010 10:00:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=5108 Pfizer Declares An 18-Cent Third-Quarter 2010 Dividend http://pfizer.mediaroom.com/index.php?s=5149&item=5010 NEW YORK, June 24 /PRNewswire-FirstCall/ -- The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent third-quarter 2010 dividend on the company's common stock, payable September 1, 2010, to shareholders of record at the close of business on August 6, 2010.   (Logo: http://photos.prnewswire. Thu, 24 Jun 2010 16:15:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=5010 Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program http://pfizer.mediaroom.com/index.php?s=5149&item=5009 NEW YORK, June 23 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA). Wed, 23 Jun 2010 17:20:20 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=5009 Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® http://pfizer.mediaroom.com/index.php?s=5149&item=4960 NEW YORK, June 21 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that based on discussions with the U.S. Mon, 21 Jun 2010 15:32:02 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=4960 Caduet Reduces 10-Year Calculated Risk Of Coronary Heart Disease, Fatal Cardiovascular Disease http://pfizer.mediaroom.com/index.php?s=5149&item=4967 OSLO, Norway, June 21 – Caduet® (amlodipine besylate/atorvastatin calcium) was associated with a significantly reduced calculated 10-year risk of coronary heart disease (CHD) based on a Framingham risk assessment model. In addition, Caduet was shown to reduce calculated fatal cardiovascular disease (CVD) risk, as a secondary trial endpoint based on the SCORE risk assessment model. Mon, 21 Jun 2010 13:56:31 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=4967 New CELEBREX® (celecoxib) Study Using Novel Endpoint, Published by The Lancet, Contributes to Knowledge of NSAID-Associated Gastrointestinal Adverse Events http://pfizer.mediaroom.com/index.php?s=5149&item=4852 NEW YORK, June 17 /PRNewswire-FirstCall/ -- Pfizer Inc. Thu, 17 Jun 2010 07:46:00 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=4852 Pfizer Announces Creation Of Rare Disease Research Unit http://pfizer.mediaroom.com/index.php?s=5149&item=4966 NEW YORK, N.Y., June 14 - Pfizer Inc. today announced the creation of a new Research Unit focused on rare diseases. Mon, 14 Jun 2010 13:54:08 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=4966 Capsugel France Facility Receives FDA Approval http://pfizer.mediaroom.com/index.php?s=5149&item=4965 PLOËRMEL, France, June 14 - Capsugel, the world’s leading hard capsule manufacturer and an innovator in drug delivery systems, announced the U.S. Food and Drug Administration (FDA) classified its facility in Ploërmel, France as acceptable to manufacture naproxcinod, following a New Drug Application filing by a Capsugel customer. Mon, 14 Jun 2010 13:51:24 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=4965 Pfizer Animal Health To Expand Access To E. Coli O157 Vaccine From Epitopix For Beef Cattle http://pfizer.mediaroom.com/index.php?s=5149&item=4964 NEW YORK, N.Y., June 11 - Pfizer Animal Health today furthered its commitment to safe food from cattle by announcing a global licensing agreement with Epitopix that will expand access to its conditionally licensed Escherichia Coli Bacterial Extract vaccine* to U.S. Fri, 11 Jun 2010 13:42:41 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=4964 Averroes Study of Investigational Agent Apixaban Closes Early Due to Clear Evidence of Efficacy http://pfizer.mediaroom.com/index.php?s=5149&item=4963 (PRINCETON, NJ and NEW YORK) -- JUNE 10, 2010 -- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. Thu, 10 Jun 2010 13:38:53 -0400 http://pfizer.mediaroom.com/index.php?s=5149&item=4963